MHMarie Hudson

Marie Hudson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marie Hudson has a total of 665 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Treatment patterns and outcomes of scleroderma renal crisis in the international scleroderma renal crisis survey II – An inception cohort study

    by Rayleigh Chan, Melanie Baniña, Claudie Berger, Cybele Ghossein, Sabrina Hoa, Sindhu R. Johnson, Hao Cheng Shen, Edward P. Stern, Christopher P. Denton, Marie Hudson

  • Updates on idiopathic inflammatory myopathies: partnering with patients, making progress

    by Angeles Galindo-Feria, Marie Hudson, Didem Saygin

    Was not provided for this article.

  • Does the ACR/EULAR Total Improvement Score Reflect How Individuals With Autoimmune Inflammatory Myopathies Feel and Function?

    by Valérie Leclair, Claudie Berger, Maude Bouchard-Marmen, Josiane Bourré-Tessier, Océane Landon-Cardinal, Marie Hudson

    Objective: Little is known as to whether the American College of Rheumatology/European Alliance of Associations for Rheumatology Total Improvement Score (TIS) reflects how patients with autoimmune inflammatory myopathies (AIM) feel and function. We assessed the associations between TIS and changes in the scores of a wide range of patient-reported outcomes (PROs). Methods: Adult patients with AIM and active disease at baseline who completed a 1-year follow-up visit were identified from a research cohort. PROs included a numerical rating scale for pain, the Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-Fatigue) scale, the Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form v1.0 Fatigue 8a, the 9-item Patient Health Questionnaire (PHQ-9), and the 36-Item Short Form Health Survey (SF-36) physical and mental component summary scores (PCS and MCS, respectively). Multivariable linear regression models were generated to determine the absolute change in PRO scores for each 20-unit increase in absolute TIS. Results: We identified 65 patients with active disease for whom TIS could be calculated. At 1 year, 40% showed no improvement, 34% achieved minimal improvement, and 26% achieved moderate improvement. In adjusted models, increase in absolute TIS was associated with statistically significant improvements in pain, PROMIS-Fatigue, FACIT-Fatigue, and SF-36 PCS scores. For FACIT-Fatigue, a significant interaction was identified between age and TIS. In stratified analyses, only patients with shorter disease duration significantly improved in pain and FACIT-Fatigue scores. Conclusion: The findings of this cohort study support the use of the TIS in AIM research but also highlight potential limitations in its ability to capture outcomes across the broader AIM spectrum, particularly among older individuals and those with longer disease duration.

  • Open Access

    Distinct Systemic Sclerosis Phenotypes Related to Ethnicity: An Opportunity to Personalize Care?

    by Danick Goulet, Camille Guertin Bsc, MRCP(UK) Maggie Larché BSc MBChB, Isabelle Ferdinand, Marie Hudson, May Y. Choi, Mohammed Osman, Janet Pope, Carter Thorne Md Facp Macr, Murray Baron, et al.


  • Open Access

    Immunosuppressive Drug Use in Limited Systemic Sclerosis: An International Survey

    by Sabrina Hoa, Yicheng Mu, Marie Hudson, Janet Pope

    Objective: Current guidelines recommend immunosuppressive treatment for diffuse cutaneous systemic sclerosis but are less clear on their use in limited cutaneous systemic sclerosis (lcSSc) in the absence of internal organ complications. We conducted an international survey to understand current immunosuppressive drug prescribing patterns in lcSSc. Methods: An electronic REDCap survey was distributed to 756 general rheumatologists and 250 national and international SSc experts. Results: A total of 139 participants (14%) responded to the survey (94% were rheumatologists); 58% of respondents reported at least sometimes using immunosuppressive drugs to treat cutaneous symptoms in lcSSc, whereas 42% rarely or never did. Conversely, only 21% reported at least sometimes prescribing immunosuppression to prevent future complications in lcSSc, whereas 79% rarely or never did. Over 70% of respondents indicated that they would likely treat lcSSc in the presence of tendon friction rubs, new areas of skin thickening, increasing modified Rodnan skin scores (mRSSs), or mRSSs of 15 and above. Close to half would likely prescribe immunosuppression in the presence of mRSS of 10 to 14, anti‐topoisomerase I antibodies, or anti‐RNA polymerase III antibodies. Interestingly, a majority of respondents would likely treat lcSSc in the presence of subclinical organ involvement, including subclinical myocardial, muscle, joint, and lung disease. The top first‐line drugs of choice were mycophenolate mofetil (47%), methotrexate (28%), and hydroxychloroquine (20%). Conclusion: This international survey highlights significant heterogeneity among rheumatologists in the use of immunosuppressive drugs in lcSSc. High‐quality research is needed to guide and harmonize the approach to management in lcSSc.


  • Open Access

    Anti-synthetase Syndrome–Associated Interstitial Lung Disease: Clinical Features and Outcomes Compared with Other ILDs

    by Sangmee Bae, Francisca Bozán, Daphne Rivero-Gallegos, Giovanni Zanframundo, Eduardo Dourado, Akira Yoshida, Iazsmin Bauer Ventura, Sara Faghihi-Kashani, Aravinthan Loganathan, Gianluca Sambataro, et al.

    Objectives: To identify clinical features distinguishing anti-synthetase syndrome (ASyS)-related ILD (ASyS-ILD) from non-ASyS ILD and to compare outcomes across ILD subgroups.Methods: We utilized an international, real-world physician-reported database to compare ASyS-ILD and ILD related to other causes. Comparative analysis was performed against the overall control group, and the five main control ILD disease subgroups. Logistic regression assessed associations with supplemental oxygen use and ILD-hospitalization, and Cox proportional hazards models evaluated associations with all-cause mortality. Results: Among 1,557 ASyS-ILD and 828 controls, ASyS-ILD patients were younger, had more acute onset, and had worse restrictive physiology. Nonspecific interstitial pneumonia (NSIP) was the most common radiological pattern across all groups. In ASyS-ILD, NSIP (55%) was followed by organizing pneumonia (OP, 19%), similar to ILD in dermatomyositis (DM) with and without MDA5 antibodies (NSIP 53% and 64%, OP 32% and 11%, respectively). NSIP remained common in rheumatoid arthritis (RA) and systemic sclerosis (SSc) ILD (39% and 59%) but was followed by usual interstitial pneumonia (36% and 14%). Compared with controls, ASyS-ILD had higher odds of hospitalization (OR 1.81, 95%CI 1.38-2.37). Mortality in ASyS-ILD was primarily pulmonary then cardiovascular, Five-year survival in ASyS-ILD was 94.7% which was comparable or higher than most control subgroups, except anti-MDA5-associated ILD (90.3%). ASyS-ILD had higher all-cause mortality (HR 1.66, 95%CI 1.03–2.66) than controls. Conclusions: ASyS-ILD is characterized by a younger, more acute, and symptomatic onset compared with other ILDs, and is associated with higher hospitalization rates and worse mortality, underscoring its overall more severe clinical course.

  • Open Access

    Development and Validation of the Brief Support Group Leader Self‐Efficacy Scale Among Scleroderma Peer Support Group Leaders

    by Sabrina Provencher, Daphna Harel, Richard S Henry, Marie-Eve Carrier, Laura Dyas, Violet Konrad, Marie Hudson, Brett D Thombs, SPIN‐SSLED Support Group Advisory Team

    Objective: Our objective was to develop a brief Support Group Leader Self‐efficacy Scale (Brief‐SGLSS) that maintains the core content and measurement properties of the full 32‐item SGLSS among systemic sclerosis (SSc) support group leaders. Methods: Development and validation involved four steps conducted by researchers and a Support Group Advisory Team of people with SSc: (1) item content assessment and prioritization, including a Delphi process; (2) item analysis and preliminary selection, including analysis of SGLSS measurement properties using Scleroderma Patient‐centered Intervention Network–Scleroderma‐Support group Leader Education (SPIN‐SSLED) trial data and a data‐driven item resampling process; (3) advisory team input to select final Brief‐SGLSS items; and (4) comparison of convergent validity and trial change data of the Brief‐SGLSS and full SGLSS. Results: Items were categorized into six content themes. Two Delphi rounds resulted in one item excluded from consideration. A 6‐item Brief‐SGLSS was selected at the consensus advisory panel meeting based on the resampling process and content and statistical considerations. The Pearson correlation of the Brief‐SGLSS and full SGLSS was 0.96. The standardized mean difference between intervention (n = 74) and waitlist (n = 72) groups in the SPIN‐SSLED trial immediately post intervention was 0.93 (95% confidence interval [CI] 0.59–1.27) for the full 32‐item SGLSS and 0.93 (95% CI 0.58–1.27) for the Brief‐SGLSS. Convergent validity of the Brief‐SGLSS and full SGLSS with other measures was similar. Conclusion: The 6‐item SGLSS is shorter and more feasibly implemented than the full SGLSS and maintains similar measurement properties.

  • Scleromyositis – The new frontier

    by Marie Hudson, Yves Troyanov, Océane Landon-Cardinal


  • Getting It Right for Our Patients

    by Marie Hudson, Daniel H. Solomon